Bill > SCR29

This concurrent resolution requests the Hawaii State Auditor to assess the social and financial effects of mandating health insurance coverage for biomarker testing. Biomarker testing involves analyzing a patient's tissue, blood, or other biospecimen to measure biological characteristics that can indicate normal or pathogenic processes, such as gene mutations or protein expressions. The resolution highlights that biomarker tests are crucial for various medical purposes, including disease screening, diagnosis, predicting treatment responses, monitoring treatment progress, and estimating prognosis across conditions like cancer, Alzheimer's disease, and rheumatoid arthritis. Specifically, the resolution asks the Auditor to evaluate the potential impacts of House Bill No. 553, H.D. 1, which would require insurers to provide coverage for medically necessary biomarker testing starting January 1, 2026. The Auditor is requested to submit a report with findings and recommendations no later than twenty days before the 2026 Regular Legislative Session, and to transmit copies of the resolution to the Auditor, Director of Commerce and Consumer Affairs, and Insurance Commissioner.

Health and Social Services

https://www.capitol.hawaii.gov/session/measure_indiv.aspx?billtype=SCR&billnumber=29&year=2025